- Report
- May 2023
- 143 Pages
Global
From €1744EUR$1,800USD£1,494GBP
€2181EUR$2,250USD£1,868GBP
- Report
- February 2024
- 175 Pages
Global
From €4846EUR$5,000USD£4,150GBP
- Report
- January 2024
- 175 Pages
Global
From €4846EUR$5,000USD£4,150GBP
- Report
- November 2023
- 144 Pages
Global
From €2422EUR$2,499USD£2,074GBP
- Report
- October 2023
- 181 Pages
Global
From €4749EUR$4,900USD£4,067GBP
- Report
- October 2023
- 190 Pages
Global
From €4749EUR$4,900USD£4,067GBP
- Report
- November 2021
- 295 Pages
Global
From €2665EUR$2,750USD£2,283GBP
€5330EUR$5,500USD£4,565GBP
- Report
- August 2022
- 109 Pages
Global
From €4603EUR$4,750USD£3,943GBP
- Report
- July 2023
- 110 Pages
Global
From €3500EUR$3,869USD£3,103GBP
- Report
- January 2021
- 144 Pages
China, Global
From €3000EUR$3,316USD£2,659GBP
- Report
- April 2024
- 50 Pages
Global
From €2568EUR$2,650USD£2,200GBP
- Report
- April 2022
- 210 Pages
Global
From €5591EUR$5,769USD£4,788GBP
- Report
- April 2023
- 147 Pages
Global
From €5814EUR$5,999USD£4,979GBP
Posaconazole is an antifungal drug used to treat a variety of fungal infections, including those caused by Aspergillus and Candida species. It is a triazole antifungal, which works by inhibiting the synthesis of ergosterol, a key component of fungal cell membranes. Posaconazole is used to treat serious fungal infections in patients who are immunocompromised, such as those with HIV/AIDS, cancer, or organ transplant recipients. It is also used to prevent fungal infections in patients who are at high risk of developing them.
Posaconazole is available in both oral and intravenous formulations, and is typically used in combination with other antifungal drugs. It is generally well tolerated, with the most common side effects being nausea, vomiting, and diarrhea.
Posaconazole is a key drug in the infectious diseases drugs market, as it is used to treat a variety of serious fungal infections. It is an important treatment option for immunocompromised patients, and is also used to prevent fungal infections in high-risk patients.
Companies in the posaconazole market include Merck & Co., Inc., Pfizer, Inc., Astellas Pharma, Inc., and Dr. Reddy's Laboratories. Show Less Read more